Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a Phase II, randomized, open‐label, active‐controlled study designed to evaluatethe preliminary efficacy and safety of a single subretinal administration of JWK001 atdifferent dose levels in patients with neovascular age‐related macular degeneration.
Epistemonikos ID: 21b67597a301f6cf51ef12bd4e0b12e270603c08
First added on: Aug 20, 2026